"Head and Neck Neoplasms" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)
| Descriptor ID |
D006258
|
| MeSH Number(s) |
C04.588.443
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Head and Neck Neoplasms".
Below are MeSH descriptors whose meaning is more specific than "Head and Neck Neoplasms".
This graph shows the total number of publications written about "Head and Neck Neoplasms" by people in this website by year, and whether "Head and Neck Neoplasms" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 1 | 0 | 1 |
| 1999 | 1 | 0 | 1 |
| 2002 | 1 | 1 | 2 |
| 2003 | 3 | 0 | 3 |
| 2004 | 3 | 0 | 3 |
| 2005 | 1 | 0 | 1 |
| 2006 | 2 | 0 | 2 |
| 2007 | 2 | 0 | 2 |
| 2008 | 2 | 0 | 2 |
| 2009 | 2 | 0 | 2 |
| 2010 | 4 | 1 | 5 |
| 2011 | 1 | 0 | 1 |
| 2012 | 1 | 0 | 1 |
| 2014 | 2 | 0 | 2 |
| 2015 | 2 | 0 | 2 |
| 2016 | 3 | 0 | 3 |
| 2017 | 3 | 1 | 4 |
| 2018 | 2 | 0 | 2 |
| 2019 | 1 | 0 | 1 |
| 2020 | 3 | 0 | 3 |
| 2021 | 3 | 0 | 3 |
| 2022 | 9 | 0 | 9 |
| 2024 | 7 | 0 | 7 |
To return to the timeline,
click here.
Below are the most recent publications written about "Head and Neck Neoplasms" by people in Profiles.
-
Radiotherapy with cetuximab or durvalumab for locoregionally advanced head and neck cancer in patients with a contraindication to cisplatin (NRG-HN004): an open-label, multicentre, parallel-group, randomised, phase 2/3 trial. Lancet Oncol. 2024 Dec; 25(12):1576-1588.
-
Optimizing Therapy: The Art and Science of Modern Head and Neck Radiation. Int J Radiat Oncol Biol Phys. 2024 Jul 01; 119(3):709-715.
-
Standardised definitions and diagnostic criteria for extranodal extension detected on histopathological examination in head and neck cancer: Head and Neck Cancer International Group consensus recommendations. Lancet Oncol. 2024 Jul; 25(7):e286-e296.
-
Criteria for the diagnosis of extranodal extension detected on radiological imaging in head and neck cancer: Head and Neck Cancer International Group consensus recommendations. Lancet Oncol. 2024 Jul; 25(7):e297-e307.
-
Assessment of endpoint definitions in recurrent and metastatic mucosal head and neck squamous cell carcinoma trials: Head and Neck Cancer International Group consensus recommendations. Lancet Oncol. 2024 Jul; 25(7):e308-e317.
-
Assessment of endpoint definitions in curative-intent trials for mucosal head and neck squamous cell carcinomas: Head and Neck Cancer International Group consensus recommendations. Lancet Oncol. 2024 Jul; 25(7):e318-e330.
-
Exposure to Secondhand Smoke Extract Increases Cisplatin Resistance in Head and Neck Cancer Cells. Int J Mol Sci. 2024 Jan 14; 25(2).
-
MiR-205-5P AS POTENTIAL BIOMARKER AND THERAPEUTIC TARGET IN HEAD AND NECK SQUAMOUS CELL CARCINOMA. Exp Oncol. 2022 12; 44(4):337-338.
-
18 F-fludeoxyglucose positron emission computed tomography (18 F-FDG-PET/CT) versus 68 Ga-DOTATATE-PET/CT in patients with head and neck cancer: Comparisons and implications for treatment. Head Neck. 2023 02; 45(2):347-354.
-
MICRORNA-31 AS A POTENTIAL THERAPEUTIC BIOMARKER FOR?ORAL SQUAMOUS CELL CARCINOMA: CURRENT EVIDENCE AND FUTURE PROSPECTS. Exp Oncol. 2022 11; 44(3):263-264.